Stock Research for CLVS


Featured Broker: Ally Invest

Get the due diligence for another stock.


CLVS Stock Chart & Research Data

The CLVS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CLVS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CLVS Due diligence Resources & Stock Charts

The CLVS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CLVS Detailed Price Forecast - CNN Money CNN View CLVS Detailed Summary - Google Finance
Yahoo View CLVS Detailed Summary - Yahoo! Finance Zacks View CLVS Stock Research & Analysis -

Stock Analysis

TradeIdeas View CLVS Trends & Analysis - Trade-Ideas Barrons View CLVS Major Holders - Barrons
NASDAQ View CLVS Call Transcripts - NASDAQ Seeking View CLVS Breaking News & Analysis - Seeking Alpha
Spotlight View CLVS Annual Report - OTC Report View CLVS OTC Short Report -
TradeKing View CLVS Fundamentals - TradeKing Charts View CLVS SEC Filings - Bar Chart
WSJ View Historical Prices for CLVS - The WSJ Morningstar View Performance/Total Return for CLVS - Morningstar
MarketWatch View the Analyst Estimates for CLVS - MarketWatch CNBC View the Earnings History for CLVS - CNBC
StockMarketWatch View the CLVS Earnings - StockMarketWatch MacroAxis View CLVS Buy or Sell Recommendations - MacroAxis
Bullish View the CLVS Bullish Patterns - American Bulls Short Pains View CLVS Short Pain Metrics -

Social Media Mentions

StockTwits View CLVS Stock Mentions - StockTwits PennyStocks View CLVS Stock Mentions - PennyStockTweets
Twitter View CLVS Stock Mentions - Twitter Invest Hub View CLVS Investment Forum News - Investor Hub
Yahoo View CLVS Stock Mentions - Yahoo! Message Board Seeking Alpha View CLVS Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CLVS - Insider Cow View Insider Transactions for CLVS - Insider Cow
CNBC View CLVS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CLVS - OTC Markets
Yahoo View Insider Transactions for CLVS - Yahoo! Finance NASDAQ View Institutional Holdings for CLVS - NASDAQ

Stock Charts

FinViz View CLVS Stock Insight & Charts - StockCharts View CLVS Investment Charts -
BarChart View CLVS Stock Overview & Charts - BarChart Trading View View CLVS User Generated Charts - Trading View

Latest Financial News for CLVS

SEC fines Clovis Oncology Inc., executives $20.8 million for lying about cancer drug effectiveness
Posted on Tuesday September 18, 2018

Clovis Oncology Inc., will pay $20 million to settle charges by the Securities and Exchange Commission that it misled investors about the effectiveness of the company's developmental lung cancer drug, rociletinib, or Roci, according to an SEC press release. Its CEO Patrick Mahaffy, and Erle Mast, the company's former CFO, also settled charges. Over a four-month period starting in July 2015, the company and Mahaffy used its investor presentations, press releases, and SEC filings to inaccurately state that the drug was effective 60% of the time, meaning that in 60% of patients Roci caused targeted tumors to shrink, despite knowing actual results were much lower. Clovis raised approximately $298 million in a public stock offering in July 2015, but its stock price dropped by 70% in November 2015 after disclosing the true effectiveness rate, 28%. The company stopped development of the drug in May 2016. The defendants did not admit or deny the allegations. Mahaffy agreed to a $250,000 penalty and Mast agreed to pay a $100,000 penalty and to pay back $454,145, in proceeds from selling Clovis stock during the relevant period at the inflated prices.

Clovis Oncology, execs to pay $20 million to settle SEC charges
Posted on Tuesday September 18, 2018

U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday. According to the SEC, Clovis continually told investors that its drug, Roci, caused targeted tumors to shrink in 60 percent of patients, when data showed it had actually caused tumor shrinkage in 42 percent of patients. Once Clovis disclosed the true efficacy rate at the end of 2015, its stock price dropped about 70 percent, the SEC added.

See what the IHS Markit Score report has to say about Clovis Oncology Inc.
Posted on Thursday September 13, 2018

Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

Clovis Oncology to Present at the Morgan Stanley Global Healthcare Conference
Posted on Thursday September 06, 2018

Clovis Oncology, Inc. (CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 16th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:55 PM Eastern Time. The conference will be held at the Grand Hyatt New York in New York City. A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at

Stock Market & Investing Books

Enter a stock symbol to view the stock details.